Literature DB >> 9813671

Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro.

M Chillón1, J H Lee, A Fasbender, M J Welsh.   

Abstract

Development of neutralizing antibodies is an important hindrance that limits repeated administration of adenoviral vectors for gene transfer. One way to avoid this problem would be to coat the virus with a substance that could shield it from antibodies. To develop such a system, we coated negatively-charged adenovirus with the cationic lipid GL-67 and included polyethylene glycol (PEG) in the complex as dioleoylphosphatidylethanolamine-PEG (DOPE-PEG). This complex enhanced gene transfer to cells that were difficult to infect both in vitro and in vivo. GL-67/DOPE-PEG coated the virus and prevented antibody binding. As a result, 50-fold higher concentrations of immune plasma were required for neutralization than with adenovirus alone. However, use of the complex provided no appreciable protection from neutralization when vector was delivered in vivo to immunized animals. These data are the first to suggest that formation of a complex around adenovirus can partially shield it from immune plasma in vitro. Despite the lack of protection in vivo, these results suggest the feasibility of developing a system in which the virus is effectively shielded from neutralizing antibodies and capable of repeat administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813671     DOI: 10.1038/sj.gt.3300665

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  32 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 2.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

3.  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Authors:  Lennart Holterman; Ronald Vogels; Remko van der Vlugt; Martijn Sieuwerts; Jos Grimbergen; Jorn Kaspers; Eric Geelen; Esmeralda van der Helm; Angelique Lemckert; Gert Gillissen; Sandra Verhaagh; Jerome Custers; David Zuijdgeest; Ben Berkhout; Margreet Bakker; Paul Quax; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 4.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 5.  Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.

Authors:  Maria Yanqing Chen; Susan S Butler; Weitong Chen; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-11-08

6.  Impact of lentiviral vector-mediated transduction on the tightness of a polarized model of airway epithelium and effect of cationic polymer polyethylenimine.

Authors:  Stefano Castellani; Sante Di Gioia; Teresa Trotta; Angela Bruna Maffione; Massimo Conese
Journal:  J Biomed Biotechnol       Date:  2010-06-21

Review 7.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

8.  Lentivirus vector can be readministered to nasal epithelia without blocking immune responses.

Authors:  Patrick L Sinn; Ariadna C Arias; Kim A Brogden; Paul B McCray
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

9.  Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor.

Authors:  E M Lee; S H Hong; Y J Lee; Y H Kang; K C Choi; S H Choi; I H Kim; S J Lim
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-16       Impact factor: 4.553

10.  Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.

Authors:  Laura M Kasman; Sutapa Barua; Ping Lu; Kaushal Rege; Christina Voelkel-Johnson
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.